Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories, Inc. (NASDAQ: MLAB) is described in its public communications as a global leader in the design and manufacture of life science tools and critical quality control solutions. Its news flow reflects this focus, with regular updates related to regulated applications in the pharmaceutical, healthcare, and medical device industries.
Visitors to this MLAB news page can review company-issued press releases covering financial results, divisional performance, and capital structure decisions. Mesa frequently announces quarterly results for its four divisions—Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics—highlighting revenues, organic and core organic revenues growth, and commentary on factors such as tariffs, foreign exchange, and geographic trends.
The news stream also includes dividend declarations, where the Board of Directors approves a regular quarterly dividend on Mesa’s common stock, along with record and payment dates. In addition, Mesa issues releases about investor conference participation and healthcare conference presentations, providing context for how management communicates with the investment community.
Another recurring theme in Mesa’s news is financing and balance sheet activity, such as the execution of strategic financing plans, use of its credit facility, and repayment or settlement of convertible notes. These items offer insight into how the company manages its capital structure alongside its operating performance.
By following this page, readers can access a chronological view of Mesa’s official announcements, including earnings releases, dividend decisions, conference appearances, and financing updates, all drawn from the company’s own disclosures.
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced significant financial results for the second fiscal quarter and six months ended September 30, 2022. Revenues surged 64% to $58.7M for the quarter and 54% to $109.2M year-to-date. Despite the revenue increase, operating income decreased 5% for the quarter and turned negative with a loss of $599K for the six months. Adjusted operating income rose 56% for the quarter, reaching $15.5M. Organic growth was 12% and 8% for the quarter and year-to-date, respectively. The company cited challenges from supply chain issues and currency fluctuations.
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced a quarterly dividend of $0.16 per share, payable on December 15, 2022, to shareholders on record by November 30, 2022. The company, based in Lakewood, Colorado, designs and manufactures life science tools and quality control solutions for the pharmaceutical and healthcare industries. Mesa’s commitment to ensuring product integrity and improving safety highlights its position as a leader in regulated applications within these sectors.
Mesa Laboratories (NASDAQ:MLAB) reported a 44% increase in revenues to $50,453 for 1Q23 compared to 1Q22. However, operating income fell by 247% to $(4,594), and net loss amounted to $(1,438), a 172% decline year-over-year. The adjusted operating income (AOI) dropped 33% to $6,158, influenced by unusual costs of $356. Revenue growth was hindered by China lockdowns and foreign exchange impacts, with organic growth at 3%. Notably, Clinical Genomics faced challenges, while Biopharmaceutical Development showed 24% growth.
Mesa Laboratories, Inc. (NASDAQ: MLAB) announced a quarterly dividend of $0.16 per share, payable on September 15, 2022, to shareholders on record as of August 31, 2022. The company is a leader in life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device sectors, focusing on product integrity and safety.
Mesa Laboratories, Inc. (NASDAQ:MLAB) appointed Tony Tripeny to its Board of Directors effective June 23, 2022. Tripeny previously served as Executive Vice President and CFO of Corning, retiring in May 2022. His extensive financial background will enhance the Board, which now has eight members, six of whom are independent. The Board aims for ongoing refreshment, and Tripeny's expertise is expected to support Mesa's acquisition strategy and overall business evolution, as emphasized by Chairman John Sullivan.
Mesa Laboratories, Inc. (NASDAQ:MLAB) reported a 55% revenue increase for 4Q22, totaling $58,879 thousand, and a 38% rise for FY22 at $184,335 thousand. Despite this growth, operating income fell 103% for the quarter to $(110) thousand and 62% for the year to $4,702 thousand. Non-GAAP adjusted operating income excluding unusual items increased 31% for 4Q22 and 29% for FY22. Future risks include anticipated impacts from COVID-related lockdowns in China, potentially affecting revenues in the Clinical Genomics segment.
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced a quarterly dividend of $0.16 per share, payable on June 15, 2022, to shareholders of record as of May 31, 2022. This reflects the company's commitment to returning value to its shareholders. Mesa is a leader in providing life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries, aiming to enhance product integrity and safety.
Mesa Laboratories reported robust financial results for 3Q22, with a 60% increase in revenues to $54,696 and a 31% increase for the nine months to $125,456 compared to last year. However, the company faced an operating loss of $(2,512), a significant decline from a profit of $22 in 3Q21. Despite this, non-GAAP adjusted operating income rose 73% for the quarter, reflecting strong organic growth of 12%. The company emphasized its strategic acquisition of Agena Bioscience and further growth in its biopharmaceutical and clinical genomics sectors, signaling positive long-term prospects.
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a quarterly dividend of $0.16 per share, payable on March 15, 2022, to shareholders of record by February 28, 2022. Mesa is recognized as a leader in providing life science tools and quality control solutions in the pharmaceutical and healthcare sectors. The company emphasizes ensuring product integrity and enhancing safety for patients and workers globally. This announcement reflects Mesa's commitment to returning value to shareholders despite the ongoing uncertainties in the market.
Mesa Laboratories, Inc. (NASDAQ:MLAB) reported its financial results for 2Q22, highlighting a revenue increase of 12% to $35,840 thousands, while net income rose 39% to $3,720 thousands or $0.70 per diluted share. However, operating income decreased 6% to $4,201 thousands. For the six months, revenues grew 14% to $70,760 thousands, with net income climbing 47% to $5,715 thousands or $1.07 per diluted share. The company attributed the growth to strong performance in sterilization and disinfection, although it faced challenges in the Instruments division due to supply chain issues.
FAQ
What is the current stock price of Mesa Laboratories (MLAB)?
What is the market cap of Mesa Laboratories (MLAB)?
